Chronic epilepsy—modeled via pentylenetetrazol (PTZ) in 32 male Wistar rats—produced measurable diaphragm contractile suppression, verified by electrocorticography. The mechanism involved inhibition of SERCA2 (Atp2a2 mRNA downregulation), subsequent intracellular Ca²⁺ overload, and upregulation of pro-apoptotic markers Casp-3, Casp-9, and Bax alongside Bcl-2 suppression. Daily resveratrol at 5 mg/kg restored basal contractility, improved fatigue resistance, re-normalized Ca²⁺ homeostasis, and shifted the apoptotic balance back toward survival signaling.
The diaphragm is chronically underexamined in epilepsy research, yet respiratory dysfunction is a principal contributor to sudden unexpected death in epilepsy (SUDEP)—a leading cause of epilepsy-related mortality. This study mechanistically links seizure burden to a specific skeletal muscle calcium-handling defect, which is a meaningful conceptual advance. SERCA2 is the same pump targeted in cardiac research, suggesting shared therapeutic leverage across muscle types. Resveratrol's known SIRT1 activation and anti-inflammatory properties may partly explain its SERCA2-preserving effect, though the causal chain remains incompletely mapped here.
Limitations are substantial: the n=8 per group is small, the model is rodent-only, and the 5 mg/kg rat dose does not translate straightforwardly to human supplementation. Resveratrol also has notoriously poor oral bioavailability in humans. Still, as a mechanistic proof-of-concept illuminating a neglected pathway between seizure activity and respiratory muscle failure, this work is genuinely incremental and points toward SERCA2 as a tractable therapeutic target in epilepsy-associated respiratory compromise.
